{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 40 of 51', 'Study ID RCB: 2020-A00652-37', 'The Clinical Research Associate (CRA) will always refer to the currently valid version of the', 'Monitoring Plan. Monitoring will be performed by outsource consultant according to validated', 'procedures as detailed in the Monitoring Plan.', '9.9.3 Data validation', 'All data management activities will be described in the Data Management Plan.', 'During the study, data queries will be generated for data items that are potentially erroneous', 'and require appropriate clarification or correction. Prior to database lock, statistical', 'verification of the data will be undertaken in order to further assure data quality.', \"Over the course of the study, the investigator and the members of the investigator's team\", 'agree to be available during regular Quality Control visits by the Clinical Research Associate.', 'During these visits, the following points will be reviewed:', '-', 'Signed informed consent;', '-', 'quality of the data collected in the CRFs: accuracy, missing data, consistency of', \"the data with the 'source' documents (medical files, appointment books, original copies of\", 'laboratory results, etc.).', '9.10 Limitations of Research Methods', 'The complementary value of observational studies relies on their robustness for extrapolation', 'to the background environment that they aim to represent. Thus, the study population shall', 'be representative which means minimization of site selection bias and patient selection bias.', 'In studies of patient treatments, the treatment must be representative, meaning the existence', 'of the study should not impact prescription habits.', 'However in the current study we are observing Kyntheum users, the estimates will be', 'affected by selection bias, e.g. Confounding by indication and channelling bias. Those patients', 'the dermatologist chooses to treat with Kyntheum in the first time after launch, are likely to', 'be the most severe patients who have failed on other treatments available (bias by indication)', 'and those patients that are \"channelized\" to the study sites and further chosen as study', 'subjects might differ systematically from that group of patients we are trying to describe', '(channelling bias). The influence of channelling bias is tried minimized by consecutive', 'enrolment, ensuring that patients are not chosen by the investigator to participate in the', 'study. Additionally we expect selection bias due to informed consent, confounding by missing', 'data and attrition depending on disease severity.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 41 of 51', 'Study ID RCB: 2020-A00652-37', 'Acknowledging that the study is prone to many sources of bias and confounding, the design', 'of this study has been optimized to reflect the patient journeys to the extent possible.', '9.11 Other Aspects', 'Audits and Inspections', 'The Quality Assurance (QA) unit at LEO may audit the study to ensure that study procedures', 'comply with the protocol and LEO standard operating procedures, and that collected data is', 'correct and complete.', 'Representatives from/IEC or Competent Authority may wish to inspect the study on site. Upon', 'receiving notification of such inspection, the Study Site Responsible must immediately contact', 'LEO and must make the records available as requested.', 'Archiving of Study Data and Documentation', 'During the course of the study the Site Responsible must as a minimum file the essential', 'documents (Section 3), the protocol (all used versions), the list of participating patients, the', 'written informed consents, the CRFs and the progress reports in the Study Site File. After final', 'database lock the Site Responsible must as a minimum store the list of participating patients', 'and the signed Informed Consent Forms on site for at least 5 years or according to local', 'regulations (if a longer archiving period is required). The Site Responsible should store', 'additional study documentation for a longer period of time as required by any local', 'regulations and/or hospital/clinic requirement.', 'LEO shall maintain the data and the documentation relating to the study for at least 5 years', 'after the studied product is no longer on the market in any country.', '10', 'Protection of human subjects', 'This study is a non-interventional study where the existence of the study has no impact on the', 'patient. The treatment of the participating patients will not be any different from patients not', \"participating in the study, except for collection of informed consent to use of the patient's\", 'data. Informed consent from the patients shall be collected in order to allow collection of non-', 'standard data such as the psychosocial component and for data monitoring purposes.', 'The Site Study Responsible must give the patient (and if applicable, legal guardian) oral and', 'written information about the study in a form that the patient (or legal guardian) can', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}